Login / Signup

Evaluation of pulmonary side effects in prolactinoma patients treated with cabergoline.

Ozlem Soyluk SelcukbiricikZuleyha BingolSema C DogansenNeslihan KurtulmusSeher TanrikuluSema Yarman
Published in: Endokrynologia Polska (2023)
CAB appears to be safe in terms of pulmonary functions with a median cumulative dose of 192 mg in prolactinoma patients.
Keyphrases
  • end stage renal disease
  • pulmonary hypertension
  • newly diagnosed
  • ejection fraction
  • chronic kidney disease
  • peritoneal dialysis
  • prognostic factors
  • patient reported outcomes